Cargando…

Pioglitazone Attenuates Drug-Eluting Stent-Induced Proinflammatory State in Patients by Blocking Ubiquitination of PPAR

The inflammatory response after polymer-based drug-eluting stent (DES) placement has recently emerged as a major concern. The biologic roles of peroxisome proliferator-activated receptor-γ (PPAR-γ) activators thiazolidinedione (TZD) remain controversial in cardiovascular disease. Herein, we investig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhongxia, Zhang, Tao, Sun, Lizhe, Li, Ruifeng, Wei, Yuanyuan, Fan, Xiaojuan, Yuan, Zuyi, Liu, Junhui, Chen, Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923578/ https://www.ncbi.nlm.nih.gov/pubmed/27403152 http://dx.doi.org/10.1155/2016/7407153

Ejemplares similares

Corrigendum to “Pioglitazone Attenuates Drug-Eluting Stent-Induced Proinflammatory State in Patients by Blocking Ubiquitination of PPAR”
por: Wang, Zhongxia, et al.
Publicado: (2019)

Nanoporous CREG-Eluting Stent Attenuates In-Stent Neointimal Formation in Porcine Coronary Arteries
por: Deng, Jie, et al.
Publicado: (2013)

Effect of Pioglitazone on In-Stent Restenosis after Coronary Drug-Eluting Stent Implantation: A Meta-Analysis of Randomized Controlled Trials
por: Zhang, Ming-duo, et al.
Publicado: (2014)

A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients
por: Ouyang, Hang, et al.
Publicado: (2021)

Effects of a Matrix Metalloproteinase Inhibitor-Eluting Stent on In-Stent Restenosis
por: Song, Jian-bo, et al.
Publicado: (2020)

Effects of Low Dose Pioglitazone on Restenosis and Coronary Atherosclerosis in Diabetic Patients Undergoing Drug Eluting Stent Implantation
por: Lee, Hye Won, et al.
Publicado: (2013)

Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized Trials
por: Alazzoni, Ashraf, et al.
Publicado: (2012)

Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial
por: Arroyo, Diego, et al.
Publicado: (2014)

Midterm Clinical Impacts of Biodegradable Polymer Everolimus-Eluting Stents Compared with Durable Polymer Everolimus-Eluting Stents: A 3-Year Propensity-Matched Study
por: Matsuda, Hiroaki, et al.
Publicado: (2020)

Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis
por: Wang, Guozhong, et al.
Publicado: (2019)

The Predictors of Target Lesion Revascularization and Rate of In-Stent Restenosis in the Second-Generation Drug-Eluting Stent Era
por: Zheng, Chengbin, et al.
Publicado: (2019)

Downregulation of the Proinflammatory State of Circulating Mononuclear Cells by Short-Term Treatment with Pioglitazone in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease
por: Pfützner, Andreas, et al.
Publicado: (2011)

Comparison of a drug-eluting balloon first and then bare metal stent with a drug-eluting stent for treatment of de novo lesions: study protocol of a randomized controlled trial
por: Park, Sang-Don, et al.
Publicado: (2013)

Estrogen-Eluting Stents
por: Ryu, Sung Kee, et al.
Publicado: (2009)

Coronary artery bypass grafting vs. drug-eluting stent implantation in patients with end-stage renal disease requiring dialysis
por: Wang, Zhi, et al.
Publicado: (2020)

Pioglitazone stabilizes atherosclerotic plaque by regulating the Th17/Treg balance in AMPK-dependent mechanisms
por: Tian, Yuling, et al.
Publicado: (2017)

Two-year Clinical Outcomes of Patients with Long Segments Drug-Eluting Stents: Comparison of Sirolimus-Eluting Stent with Paclitaxel-Eluting Stent
por: Kim, Ung, et al.
Publicado: (2011)

A randomized multicenter comparison of hybrid sirolimus-eluting stents with bioresorbable polymer versus everolimus-eluting stents with durable polymer in total coronary occlusion: rationale and design of the Primary Stenting of Occluded Native Coronary Arteries IV study
por: Teeuwen, Koen, et al.
Publicado: (2012)

Drug-Eluting Balloon versus New-Generation Drug-Eluting Stent for the Treatment of In-Stent Restenosis: An Updated Systematic Review and Meta-Analysis
por: Cui, Kong-Yong, et al.
Publicado: (2018)

Everolimus-eluting stents versus sirolimus-eluting stents in patients with cardiac allograft vasculopathy
por: Hawranek, Michał, et al.
Publicado: (2021)

Feasibility and efficacy evaluation of metallic biliary stents eluting gemcitabine and cisplatin for extrahepatic cholangiocarcinoma
por: Xiao, Jing-Bo, et al.
Publicado: (2020)

Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling
por: Gao, Hongli, et al.
Publicado: (2017)

Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity
por: Jacques, Vincent, et al.
Publicado: (2021)

Comparison of the safety and efficacy of biodegradable polymer drug-eluting stents versus durable polymer drug-eluting stents: a meta-analysis
por: Lv, Jianfeng, et al.
Publicado: (2015)

Comparisons of the Effects of Stent Eccentricity on the Neointimal Hyperplasia between Sirolimus-Eluting Stent versus Paclitaxel-Eluting Stent
por: Kim, Byeong-Keuk, et al.
Publicado: (2010)

Mid-Term Follow-Up of Drug-Eluting Stenting for In-Stent Restenosis: Bare-Metal Stents versus Drug-Eluting Stents
por: Faramarzi, Negar, et al.
Publicado: (2013)

Angiographic and clinical comparison of novel Orsiro Hybrid sirolimus-eluting stents and Resolute Integrity zotarolimus-eluting stents in all-comers with coronary artery disease (ORIENT trial): study protocol for a randomized controlled trial
por: Lee, Joo Myung, et al.
Publicado: (2013)

Everolimus-eluting coronary stents
por: Saez, Alejandro, et al.
Publicado: (2010)

Antibiotic eluting sinus stents
por: Thompson, Harrison M., et al.
Publicado: (2020)

Ureteral stent technology: Drug-eluting stents and stent coatings
por: Yang, Luo, et al.
Publicado: (2015)

The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys
por: Swanson, Christine R, et al.
Publicado: (2011)

Neoatherosclerosis after Drug-Eluting Stent Implantation: Roles and Mechanisms
por: Cui, Yuanyuan, et al.
Publicado: (2016)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Drug-Eluting Balloons versus Second-Generation Drug-Eluting Stents for Treating In-Stent Restenosis in Coronary Heart Disease after PCI: A Meta-Analysis
por: Xiu, Wen-Juan, et al.
Publicado: (2018)

Stent Fracture after Everolimus-Eluting Stent Implantation
por: Almasood, Ali S., et al.
Publicado: (2011)

Early definite stent thrombosis with everolimus-eluting stents
por: Naito, Ryo, et al.
Publicado: (2015)

Intracoronary brachytherapy for in-stent restenosis of drug-eluting stents
por: Ohri, Nisha, et al.
Publicado: (2015)

Drug eluting stents: Focus on Cypher™ sirolimus-eluting coronary stents in the treatment of patients with bifurcation lesions
por: Chieffo, Alaide, et al.
Publicado: (2007)

Two-Year Results of an Open-Label Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents
por: Velders, Matthijs A., et al.
Publicado: (2013)

Is There an Advantage of Ultrathin-Strut Drug-Eluting Stents over Second- and Third-Generation Drug-Eluting Stents?
por: Gherasie, Flavius-Alexandru, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3bado5ge2jk0e61vk0qebiij4n